Dell says the credit goes to its campaign -- 'Take Your Own Path' -- launched in October, 2008. It was the first such campaign by Dell anywhere in the world as the company mainly relied on direct marketing earlier.
India's ambitious plans to generate an additional 180,000 Mw of power in the next seven years will face hurdles if Indonesia, the second largest supplier of thermal coal, goes ahead with plans to cap coal exports to serve domestic demand.
Indian drug companies have cornered an overwhelming majority of drug approvals under the US President's Emergency Plan for AIDS Relief.
IT companies hire an average of 50 students each from engineering campuses and 20 students from management institutes. Headhunters confirm that many of the IT companies have given them mandates for hiring over the next couple of quarters. "We have seen an uptick in the hiring patterns among the IT firms. We ourselves have received good mandates from firms like Infosys and others.
Teva Women's Health filed a suit this week in the US District Court for New Jersey, claiming that Lupin had filed an abbreviated new drug application with the US Food and Drug Administration, which infringes the patents of Seasonale, its oral contraceptive that limits the number of menstrual periods women have in a year.
The newest CEO in the Tata group brings an aggressive pace and style to India's largest IT consultancy firm.
Dell's acquisition of Perot System for $3.9 billion is being seen by most analysts as a strategic call. This will give Dell an enlarged footprint. Both the companies will get a chance to diversify. Of course, it will make Dell a service powerhouse -- globally and in the country too.
Nova's new owner has decided not to pursue this project.
A German bankruptcy court has sold off Reliance Industries' polyester making subsidiary Trevira GmbH to two local entrepreneurs for an undisclosed amount.
Pricing worries remain, but bankers expect IPOs to raise over Rs 40,000 crore (Rs 400 billion) in the next few months.
Domestic drug major Cipla Ltd has signed a long-term collaboration agreement with Swiss specialty pharmaceutical major Meda, to develop and market an anti-allergic rhinitis drug for various global markets. Cipla will manufacture the drug, which will treat an ailment that causes a runny nose, and the Swiss company will market the product in Europe, Japan, Brazil, South Korea and Australia. The partners are developing the product as a nasal spray to treat allergic rhinitis.
The company, which saw a pricing pressure of 5-6 per cent in the last two quarters, believes that most of the pricing negotiations are completed and about one-third of pricing pressure has been factored in the company's guidance. However, Shibulal does not rule out some tail-wind effect in this quarter as well.
PLSL's lead molecule under development for cancer treatment has completed two Phase-I studies.
BP is apparently targeting a higher percentage of offshoring.
JSW Energy aims to generate 11,390 Mw in the country by 2015. The company has tied up with two consortiums of lenders, led by IDBI Bank and State Bank of India, respectively, for the loans. It had recently filed a draft red-herring prospectus for a Rs 3,000 crore (Rs 30 billion) public offering with market regulator Securities and Exchange Board of India.
Venture capitalists and seed fund providers receive around 500-1,200 business plans every year. The trend continued even among the student fraternity. Venture firms such as Morpheus Venture Partners and Centre for Innovation, Incubation and Entrepreneurship that work closely with students and incubator centres have seen a spurt in activity.
With increased awareness and concern over unexpected events like the 26/11 terror attack on Mumbai, Ganesh mandals (organisers of the Ganapati festival) are seeking higher insurance cover. For instance, Mumbai's most popular mandal, Lalbaughcha Raja Ganesh Mandal, has bought insurance worth Rs 4 crore (Rs 40 million).
Mumbai-based Ajanta Pharma has tied up with the Canadian vaccine maker, Medicago Inc, to commercialise Medicago's pandemic and seasonal influenza vaccines in India and other territories.
GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies.
Mushrooming app stores are offering a huge 70 per cent revenue to developers.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances